Sermorelin & GHRP-2 Blend

Related by research scope · open each to compare

Regulatory detail for this region is not available in the current seed.

Confirmed high-severity market-integrity event (enforcement / recall / counterfeit)

Transparent blend · bci-1.0 · never paid-placement

Primary name

Sermorelin & GHRP-2 Blend

Sequence not available in current seed.

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

Synthetic GHRH(1-29) fragment that stimulates pulsatile GH release via pituitary GHRHR; formerly FDA-approved as Geref (discontinued 2008). Research use only.

Sermorelin acts as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR), a Gs-protein-coupled receptor expressed on anterior pituitary somatotroph cells. Binding stimulates adenylyl cyclase, increases intracellular cyclic AMP, activates protein kinase A, and promotes both synthesis and pulsatile exocytotic release of endogenous growth hormone. Because sermorelin acts upstream of the pituitary — causing the gland to release its own GH rather than supplying exogenous hormone — the resulting GH profile mirrors physiological pulsatility and remains subject to normal negative-feedback inhibition by somatostatin, which limits the degree of GH elevation achievable. Downstream GH signalling drives hepatic IGF-1 synthesis and the anabolic, lipolytic, and growth-promoting effects associated with the GH/IGF-1 axis.

Molar mass

3357.9 g/mol

Synthetic hexapeptide GHS-R1a agonist (pralmorelin) that stimulates pulsatile GH release; approved in Japan as a GH-deficiency diagnostic agent.

GHRP-2 binds and activates GHS-R1a, a Gq/11-coupled receptor expressed on pituitary somatotrophs and hypothalamic arcuate neurons. Receptor engagement triggers phospholipase C activation, inositol trisphosphate-mediated intracellular calcium mobilisation, and exocytosis of stored GH. Simultaneously, GHRP-2 potentiates the endogenous GHRH signal in the hypothalamus and partially suppresses somatostatin tone, producing a synergistic amplification of the pulsatile GH release that exceeds either pathway alone. Cortisol and prolactin secretion are also modestly elevated, reflecting broader GHS-R1a expression outside the somatotroph axis.

Molar mass

818.0 g/mol

How much research exists, and of what maturity — never a verdict on whether it works.

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Tiulpakov AN, et al. GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers. Clin Endocrinol (Oxf). 1995;43(3):347-50. PMID 7586605. — BLEND-LEVEL (not component-level) — a genuine randomized crossover human study of THIS pairing: 8 healthy adult male volunteers received IV bolus GHRH1-29NH2 (the sermorelin peptide), GHRP-2, and the combination, each 1 mcg/kg. GHRP-2 alone produced a larger GH response than GHRH1-29NH2 alone; the combination's GH AUC was NOT significantly different from the sum of the two separate responses — the authors explicitly state synergy could not be demonstrated (possible dose-ratio masking). Pre-registry era (1995); not a completed/registered RCT, but the closest primary evidence this blend has.
• Tiulpakov AN, et al. Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature. Metabolism. 1995;44(9):1199-204. PMID 7666796. — BLEND-LEVEL — same research group's pediatric companion study: 10 children with GH insufficiency and 5 with idiopathic short stature received IV bolus GHRH1-29NH2, GHRP-2, and the combination (each 1 mcg/kg), randomized order. GH responses to the combination were compared with each peptide alone; children with GH insufficiency showed low responses to both individually. Pre-registry era; a vulnerable pediatric population — reported here strictly as historical primary literature, not a dosing protocol.
• Sinha DK, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020;9(Suppl 2):S149-S159. PMID 32257855. — Narrative review covering sermorelin, GHRP-2, GHRP-6, ibutamoren, ipamorelin as a drug class; notes a paucity of clinical-efficacy data. Does not evaluate the sermorelin+GHRP-2 combination specifically.
• Yoon S, et al. Growth hormone-releasing peptide-2: Summary Report. University of Maryland M-CERSI, prepared for FDA, 2021-01. — Scoping/systematic literature review prepared for FDA on GHRP-2 use in compounding under section 503B; includes a real practitioner-survey finding (Table 12-14; citing Sigalos et al. 2017) that GHRP-2 is prescribed in practice as part of a THREE-peptide regimen (GHRP-2 100 mcg + GHRP-6 100 mcg + sermorelin 100 mcg, SC TID) — not this exact two-component blend. Verified live 2026-07-16 (full text extracted).
• Suzuki S, et al. Clinical Usefulness of the Growth Hormone-Releasing Peptide-2 Test for Hypothalamic-Pituitary Disorder. J Endocr Soc. 2022;6(8):bvac088. PMID 35795807. — Clinical study of GHRP-2 as a diagnostic GH-stimulation test in Japanese patients; notes co-release of ACTH. Component-level (GHRP-2 alone), not blend-level.
• Wu D, Chen C, Zhang J, Bowers CY, Clarke IJ. The effects of GH-releasing peptide-6 (GHRP-6) and GHRP-2 on intracellular cAMP levels and GH secretion in ovine and rat somatotrophs. J Endocrinol. 1996;148(2):197-205. PMID 8699133. — In-vitro mechanistic study: GHRP-2 and GRF (GHRH) each raised cAMP/GH via apparently distinct receptors, and combined maximal doses produced an ADDITIVE (not multiplicative/synergistic) effect on GH release in ovine pituitary cells. Supports the mechanismCoverage 'additive' pathway entry; animal/in-vitro only, not a blend-level or human finding.

No registered human trials found for this compound.

Status

No registered trials found

Dominant research route: SC

Sermorelin: FDA-approved pediatric GHD treatment (30 mcg/kg/day SC, trade name Geref Pediatric) and adult diagnostic use; PK in 12 normal volunteers (2 mg SC, peak 5-20 min, mean absolute bioavailability ~6%). GHRP-2: SC infusion (0.1 and 1 mcg/kg/hr) studied in lean and obese humans (FDA/M-CERSI 2021 report). Combination: the real-world practitioner-channel pattern documented in the literature is a THREE-peptide SC regimen (GHRP-2 + GHRP-6 + sermorelin, 100 mcg each, TID — Sigalos et al. 2017), not a controlled study of this exact two-component blend.

Bioavailability: Sermorelin SC mean absolute bioavailability ~6% (peak 5-20 min after 2 mg SC in 12 volunteers, per the drug's label text). GHRP-2 SC infusion produces a GH rise within the infusion period in both lean and obese adults.

The dominant commercially-sold route for both peptides individually; sermorelin's own label specifies sterile lyophilized powder for SC injection after reconstitution, with site rotation. No controlled study of the two-component blend administered together by any route exists — the closest primary human co-administration evidence used the IV route (see below).

BLEND-LEVEL (corrected from the draft, which wrongly called IV 'not a route used for the blend'): Tiulpakov et al. 1995 administered IV bolus GHRH1-29NH2 (the sermorelin peptide) and GHRP-2 SEPARATELY and IN COMBINATION (1 mcg/kg each) in a randomized crossover design, in 8 healthy adult volunteers and again in 15 children with GH insufficiency/idiopathic short stature — the only primary human evidence of this pair administered together. Separately, sermorelin (Geref Diagnostic) is FDA-approved as a 1 mcg/kg single IV diagnostic agent for adult GHD, and GHRP-2 was given IV to 10 male volunteers for a metabolite-assay PK study.

Bioavailability: IV combined dosing (Tiulpakov 1995): peak GH at 20-45 min; the combination's GH AUC was not significantly different from the sum of the separate GHRH1-29NH2 and GHRP-2 responses — synergy was explicitly NOT demonstrated. IV is 100% systemic exposure by definition for either component alone.

The only route with primary human evidence of this exact pair administered together — a pharmacodynamic research finding (no synergy shown), not a dosing protocol, and not the route this pairing is commercially sold by.

GHRP-2 intranasal spray studied in a double-blind RCT of 126 prepubertal short children with GHD (placebo vs low vs high dose, twice daily for 48 weeks); an earlier Pihoker et al. series in 15 children. Sermorelin intranasal was not located in retrieved primary sources — component-level only, not a studied route for the blend.

Bioavailability: Intranasal GHRP-2 spray increased endogenous GH secretion (responder cut-off 9 ng/mL) but the serum GH AUC was judged too small to produce a growth effect; no significant height-SDS change vs placebo at 48 weeks.

Intranasal GHRP-2 was developed because oral GHRP-2 gave a poor GH response; the RCT found no growth promotion despite a transient GH increase. Not part of the sermorelin+GHRP-2 pairing's own literature.

GHRP-2: oral administration produces only a poor increase in serum GH, attributed to food-intake effects (mechanistic/observational; no robust oral PK trial retrieved). Sermorelin: no oral formulation located in retrieved primary sources.

Bioavailability: Oral GHRP-2's GH response is reported as poor and food-sensitive; no quantitative oral bioavailability value was retrieved from primary sources.

Oral is not a studied administration route for the blend; peptide instability/food interaction limits oral utility. This is an oral-stability observation, not an oral-absorption claim.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $9.18 · median $9.54 · p75 $9.88 · 6 researched vendors

Legit, COA-backed band: $8.80–$10.16/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$88

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Independent (Janoshik Analytical) HPLC purity reports for sermorelin batches — both verified live 2026-07-16 against the vendors' own posted COA pages: 99.224% (Chameleon Peptides, Batch B001) and 99.213% (Panda Peptides, Sermorelin 10mg, Batch PP2602-0377, publicly checkable at verify.janoshik.com). No GHRP-2-specific Janoshik purity figure was located in retrieved sources; no blend-specific (combined-product) aggregate purity report was found.

Independent labs cited for this compound

Two FDA-documented voluntary recalls involving sermorelin-containing compounded sterile products due to lack of sterility assurance: Talon Compounding Pharmacy (July 21, 2016, all lots of lyophilized sermorelin within expiry) and Innoveix Pharmaceuticals (July 9, 2021, compounded Sermorelin/Ipamorelin 3 mg — a different sermorelin combination, not this blend). No recall was found specifically for a Sermorelin + GHRP-2 blend product.

Buyer red-flag checklist

• GHRP-2 is not on the FDA 503A bulks list (confirmed Category 3 — Nominated Without Adequate Support, per the current May 14, 2026 FDA document) and has no applicable USP/NF monograph — compounded GHRP-2 products are not eligible for 503A exemptions (per the 2019 ImprimisRx warning letter).
• FDA-approved Sermorelin (Geref) was discontinued by the manufacturer in 2008 for commercial reasons; no FDA-approved commercial source remains, increasing reliance on compounding pharmacies and gray-market vendors.
• Multiple FDA warning letters document insanitary sterile-compounding conditions (stained HEPA filters, household dish detergent, non-sterile disinfectant in ISO-5, blocked first air) at pharmacies producing sermorelin-containing injectables.
• Two sterility-assurance recalls of compounded sermorelin-containing injectable products (Talon 2016; Innoveix 2021 — the latter a Sermorelin/Ipamorelin product, not this exact blend).
• Online 'research use only' peptide vendors (e.g., Xcel Research, 2024) marketed SERMORELIN with implied human-use claims, prompting FDA unapproved-new-drug enforcement.
• Independent lab (Janoshik) verification is vendor-submitted and batch-specific; absence of a public COA does not confirm purity, and gray-market underdosing/counterfeiting is documented for other research peptides.
• Imported peptide APIs may be subject to FDA Import Alert 66-40 detention without physical examination when the foreign manufacturer fails CGMP.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No compound-specific underdosing prevalence for a Sermorelin + GHRP-2 blend was located in retrieved independent-lab (Janoshik / MZ Biolabs / Finnrick) sources. Gray-market peptide underdosing is documented generically for other peptides (e.g., independent aggregate data shows high fail rates for some other research peptides), but that data is not specific to this blend and is not extrapolated here.

• FDA Import Alert 66-40 ('Detention Without Physical Examination of Drugs From Firms Which Have Not Met Drug GMPs'; charge Section 801(a)(3)/501(a)(2)(B), OASIS charge code DRUG GMPS) authorizes DWPE of drugs from foreign establishments found not operating in conformity with CGMPs. Verified live: the cited page is titled 'Import Alert 66-40' verbatim. Not compound-specific by name, but applies to imported peptide APIs/finished drugs including sermorelin and GHRP-2 sourced from non-compliant foreign manufacturers; an RUO label is not an importation exemption.66-40
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

The Sermorelin & GHRP-2 blend itself is not named on the WADA Prohibited List (no product-level schedule exists for a named blend). Per component, both are explicitly named under S2.2 (Peptide Hormones and Their Releasing Factors), subsection S2.2.4 'Growth hormone releasing factors': sermorelin is listed among GHRH analogues (alongside CJC-1295, tesamorelin); GHRP-2 (pralmorelin) is listed among GH-releasing peptides (GHRPs). Prohibited at all times, in- and out-of-competition.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Self-selection bias — enthusiasts and early adopters over-represented
• Anecdotal self-reporting without lab confirmation
• Vendor-affiliated and compounding-pharmacy marketing accounts present
• Survivorship bias — non-responders less likely to post long-term
• Dosage non-standardization across sources complicates comparison
• The best-documented real-world practitioner regimen in the literature (Sigalos et al. 2017; the FDA/M-CERSI 2021 GHRP-2 report) is actually a THREE-peptide combination — GHRP-2 + GHRP-6 + sermorelin, 100 mcg each, SC three times daily — not this exact two-component pairing; community discussion of 'the blend' may conflate the two- and three-peptide products.

Manually researched from reddit, youtube, x— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

A research-use-only two-peptide blend of the GHRH analog Sermorelin and the growth hormone secretagogue GHRP-2. US regulatory status: Research use only. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet